Halozyme Therapeutics (NASDAQ:HALO) Stock Price Expected to Rise, Citizens Jmp Analyst Says

Key Points

• Citizens JMP raised its Halozyme price target from $93 to $149 and maintained a “market outperform” rating, implying 41.6% upside from the stock’s then-current price.
• Analysts overall rated the stock a “Moderate Buy,” with a consensus price target of $106.09. HALO shares nevertheless fell $17.74 to $105.22 in Friday trading.
• Halozyme reported quarterly EPS of $2.39, beating estimates of $2.30, while revenue rose 39% year over year to about $493 million; the article’s news roundup also says the company raised its 2026 financial guidance.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) had its price target hoisted by equities research analysts at Citizens Jmp from $93.00 to $149.00 in a note issued to investors on Friday, Benzinga reports. The firm presently has a "market outperform" rating on the biopharmaceutical company's stock. Citizens Jmp's price target would indicate a potential upside of 41.61% from the company's current price.

A number of other research analysts have also recently issued reports on the company. Weiss Ratings raised Halozyme Therapeutics from a "buy (b-)" rating to a "buy (b)" rating in a report on Monday, August 31st. Zacks Research upgraded shares of Halozyme Therapeutics from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, October 13th. Stifel Nicolaus set a $130.00 price objective on shares of Halozyme Therapeutics in a report on Friday, October 16th. Benchmark reissued a "buy" rating on shares of Halozyme Therapeutics in a report on Tuesday, July 21st. Finally, Leerink Partners upgraded shares of Halozyme Therapeutics from a "market perform" rating to an "outperform" rating and raised their price objective for the company from $83.00 to $110.00 in a research report on Friday, August 7th. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, Halozyme Therapeutics has a consensus rating of "Moderate Buy" and a consensus price target of $106.09.

Halozyme Therapeutics Price Performance

HALO stock traded down $17.74 during midday trading on Friday, reaching $105.22. 1,273,209 shares of the company's stock traded hands, compared to its average volume of 1,949,201. The company has a 50-day simple moving average of $115.26 and a two-hundred day simple moving average of $84.57. Halozyme Therapeutics has a 1-year low of $61.22 and a 1-year high of $134.00. The company has a market cap of $11.94 billion, a price-to-earnings ratio of 31.89, a PEG ratio of 0.49 and a beta of 0.92. The company has a quick ratio of 2.31, a current ratio of 2.71 and a debt-to-equity ratio of 13.50.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last issued its quarterly earnings data on Thursday, November 5th. The biopharmaceutical company reported $2.39 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.30 by $0.09. The firm had revenue of $492.97 million during the quarter, compared to the consensus estimate of $491.63 million. Halozyme Therapeutics had a return on equity of 260.98% and a net margin of 24.86%. The business's revenue for the quarter was up 39.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.72 EPS. On average, analysts anticipate that Halozyme Therapeutics will post 8.32 earnings per share for the current year.

Insider Activity

In related news, CEO Helen Torley sold 20,000 shares of Halozyme Therapeutics stock in a transaction dated Wednesday, September 9th. The stock was sold at an average price of $107.43, for a total value of $2,148,600.00. Following the completion of the sale, the chief executive officer directly owned 767,780 shares in the company, valued at $82,482,605.40. This trade represents a 2.54% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Matthew L. Posard sold 18,996 shares of the business's stock in a transaction dated Wednesday, September 16th. The stock was sold at an average price of $107.74, for a total value of $2,046,629.04. Following the sale, the director directly owned 58,839 shares of the company's stock, valued at $6,339,313.86. This represents a 24.41% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 125,852 shares of company stock valued at $13,538,046 over the last 90 days. 2.50% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. Bank of America Corp DE bought a new position in shares of Halozyme Therapeutics during the second quarter worth $214,504,000. William Blair Investment Management LLC acquired a new position in shares of Halozyme Therapeutics in the 2nd quarter valued at $196,540,000. Jupiter Topco LLC acquired a new position in shares of Halozyme Therapeutics in the 2nd quarter valued at $105,570,000. Caisse de depot et placement du Quebec bought a new stake in shares of Halozyme Therapeutics in the 2nd quarter valued at $83,940,000. Finally, Congress Asset Management Co. increased its position in shares of Halozyme Therapeutics by 85.6% in the 3rd quarter. Congress Asset Management Co. now owns 2,281,615 shares of the biopharmaceutical company's stock valued at $251,890,000 after buying an additional 1,052,509 shares in the last quarter. Institutional investors own 97.79% of the company's stock.

Halozyme Therapeutics News Roundup

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: Revenue rose 39% year over year to a record $493 million, while royalty revenue grew 44% to $341 million. Adjusted earnings of $2.39 per share also topped the roughly $2.30 consensus estimate. Halozyme Q3 results and guidance
• Positive Sentiment: Halozyme raised its 2026 guidance, forecasting $1.86 billion–$1.925 billion in revenue and non-GAAP EPS of $8.75–$9.05. It also expanded ENHANZE collaboration agreements with three existing partners, with three programs advancing into Phase 1 development. Halozyme Q3 earnings and guidance
• Negative Sentiment: HALO fell after the earnings release even though results exceeded estimates and guidance increased. The available reports flag the share-price decline but do not identify a specific reason for the negative market reaction. Halozyme sales surprise, but stock drops

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that can improve the administration of injectable medicines. The company's primary platform, ENHANZE, uses a proprietary recombinant human hyaluronidase enzyme to facilitate the subcutaneous delivery of biologic drugs and other injectable therapies that may otherwise require intravenous infusion.

Halozyme licenses its technologies to pharmaceutical and biotechnology companies, which use them in a range of marketed and investigational products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.